PANACEABIO388.00

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,378 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-0.14-1.01-0.65-0.65
Return on Assets-0.12-0.68-0.57-0.57
Return on Capital Employed-6.09-6.58-4.13-4.13
Return on Invested Capital-2.94-7.91-4.67-3.33
Margins
EBITDA Margin-3.59-4.63-0.730.33
Operating Margin-10.15-10.86-5.90-5.90
Incremental Operating Margin4,937.5028.51
Pretax Margin0.26-1.42-1.15-1.54
Net Income Margin-0.27-1.56-1.12-1.33
Net Income to Common Margin-0.21-1.50-0.84-1.06
FCF Margin-13.92-13.89-5.85-5.85
Additional
Effective Tax Rate201.35-9.692.8513.90
Sustainable Growth Rate-0.14-1.01-0.65-0.65
Incremental Operating Margin %4,937.5028.5122.33
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.